Can Fite Biopharma stock hits 52-week low at $1.14
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Can Fite Biopharma Ltd ADR (CANF)
Can Fite Biopharma Ltd ADR stock price live, this page displays NYSE CANF stock exchange data. View the CANF premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Can Fite Biopharma Ltd ADR real time stock price chart below.
What Is the Can Fite Biopharma Ltd ADR Stock Price Today?
The Can Fite Biopharma Ltd ADR stock price today is 1.045.
What Is the Stock Symbol for Can Fite Biopharma Ltd ADR?
The stock symbol for Can Fite Biopharma Ltd ADR is "CANF."
What Stock Exchange Does Can Fite Biopharma Ltd ADR Trade On?
Can Fite Biopharma Ltd ADR is listed and trades on the NYSE stock exchange.
Is Can Fite Biopharma Ltd ADR a Good Stock to Buy?
Determining whether Can Fite Biopharma Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CANF quote. (ISIN: US13471N3008)
What Is the Can Fite Biopharma Ltd ADR Stock Price Today?
The Can Fite Biopharma Ltd ADR stock price today is 1.045.
What Is the Stock Symbol for Can Fite Biopharma Ltd ADR?
The stock symbol for Can Fite Biopharma Ltd ADR is "CANF."
What Stock Exchange Does Can Fite Biopharma Ltd ADR Trade On?
Can Fite Biopharma Ltd ADR is listed and trades on the NYSE stock exchange.
Is Can Fite Biopharma Ltd ADR a Good Stock to Buy?
Determining whether Can Fite Biopharma Ltd ADR—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CANF quote. (ISIN: US13471N3008)
1.045
-0.005(-0.48%)
Closed·
After Hours
1.080+0.035(+3.349%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.020
1.050
52 wk Range
0.980
4.690
CANF Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CANF is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.0201.050
52 wk Range
0.9804.690
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CANF Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
10.833
Upside
+936.68%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Can Fite Biopharma stock hits 52-week low at $1.22
- Investing.com
- Can Fite Biopharma stock hits 52-week low at $1.14
- Investing.com
- Can Fite Biopharma stock hits 52-week low at $1.22
- Investing.com
Can Fite Biopharma Ltd ADR Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Compare CANF to Peers and Sector
Metrics to compare | CANF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCANFPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.9x | −1.3x | −0.5x | |
PEG Ratio | −0.05 | −0.01 | 0.00 | |
Price/Book | 2.8x | 1.6x | 2.6x | |
Price / LTM Sales | 22.7x | 9.0x | 3.0x | |
Upside (Analyst Target) | - | 464.8% | 54.7% | |
Fair Value Upside | Unlock | 15.0% | 8.4% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 10.833
(+936.68% Upside)
Earnings
Latest Release
Apr 14, 2025
EPS / Forecast
-- / -0.41
Revenue / Forecast
358.00K / --
People Also Watch
FAQ
What Is the Can Fite Biopharma ADR (CANF) Stock Price Today?
The Can Fite Biopharma ADR stock price today is 1.05
What Stock Exchange Does Can Fite Biopharma ADR Trade On?
Can Fite Biopharma ADR is listed and trades on the New York Stock Exchange stock exchange.
What Is the Stock Symbol for Can Fite Biopharma ADR?
The stock symbol for Can Fite Biopharma ADR is "CANF."
What Is the Can Fite Biopharma ADR Market Cap?
As of today, Can Fite Biopharma ADR market cap is 15.29M.
What Is Can Fite Biopharma ADR's Earnings Per Share (TTM)?
The Can Fite Biopharma ADR EPS (TTM) is 0.00.
From a Technical Analysis Perspective, Is CANF a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.